Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.
Clonidine was granted FDA approval on 3 September 1974.
Clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications. A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient. An extended release tablet of clonidine is indicated for the treatment of ADHD either alo...
Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Oslo University Hospital Rikshospitalet, Oslo, Norway
Oslo University Hospital Ullevål, Oslo, Norway
University Hospital of North Norway, Tromsø, Norway
Skane University Hospital, Lund, Sweden
Marco Bartocci, Stockholm, Sweden
Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland
Clinique Saint-Pierre, Ottignies, Belgium
CUB Erasme Hospital ULB, Bruxelles, Belgium
Civil hospital Marie Curie, Charleroi, Belgium
Odense University Hospital, Odense, Fyn, Denmark
University Hospital Saint-Pierre, Brussels, Belgium
Amy Stroud, Iowa City, Iowa, United States
University of Iowa, Iowa City, Iowa, United States
Medical University Hospital LKH Graz, Graz, Austria
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.